EUVIMEDEUVIMED entdecken
Open Access

Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice

Karsten M Warwas, Anna-Lena Volckmar, Daniel Kazdal, Markus Ball, Katharina Smetanay, Christian Maurer, Carlo Fremd, Lea Sych, Verena Thewes, Jan Budczies, Albrecht Stenzinger, Andreas Schneeweiss und 1 weitere

Breast Care · 22.05.2026 · 1-15

DOI: 10.1159/000552643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Care, online erschienen am 22.05.2026. Verfasst von Karsten M Warwas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Liquid biopsy (LBx) is a minimally invasive diagnostic approach that allows molecular profiling of circulating tumor DNA. In hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, early detection of actionable mutations is critical for guiding therapy. ESR1 mutations mediate resistance to aromatase inhibitors and predict response to (oral) selective estrogen receptor degraders. Despite its clinical relevance, data on the real-world application of LBx remain limited.

Methods

We retrospectively analyzed 162 patients with HR-positive, HER2-negative metastatic breast cancer who underwent LBx testing in routine clinical care. Hybrid capture-based next-generation sequencing with high read depth (∼5,000–7,000×) was used to assess mutation profiles across a multigene panel, rather than single-gene assays such as ddPCR. Particular focus was placed on the detection of ESR1 mutations and their therapeutic implications.

Results

Of 162 patients, ESR1 mutations were detected in n = 46 (28.4%). Among these, 20 (43.5%) patients received elacestrant based on the molecular findings. LBx was feasible, rapidly implemented (∼8.7 days), and repeatable in routine practice. Detection of ESR1 mutations directly influenced treatment decisions, enabling the timely initiation of targeted endocrine therapy. Other recurrent mutations included PIK3CA, PTEN, and AKT, with potential therapeutic relevance.

Conclusion

These real-world data support the clinical utility of LBx guidance in the metastatic setting. It is a rapid, minimally invasive, and informative diagnostic method for identifying resistance mutations such as ESR1 and guiding endocrine therapy decisions, including the use of elacestrant. LBx should be integrated as early as possible in the treatment algorithm and not reserved for late treatment stages when therapeutic options are limited. Repeating LBx at the time of progression of disease should be discussed depending on possible therapeutic implications.

Schlagwörter

Stichwörter der Autor:innen

ESR1 mutationsLiquid biopsyMetastatic breast cancerNext-generation sequencingSelective estrogen receptor degraders

Autor:innen und Institutionen

  • Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
  • Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Gynecologic Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Zitieren

APA

Warwas, K. M., Volckmar, A. L., Kazdal, D., Ball, M., Smetanay, K., Maurer, C., Fremd, C., Sych, L., Thewes, V., Budczies, J., Stenzinger, A., Schneeweiss, A., & Michel, L. L. (2026). Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice. Breast Care, 1-15. https://doi.org/10.1159/000552643

Vancouver

Warwas KM, Volckmar AL, Kazdal D, Ball M, Smetanay K, Maurer C, et al. Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice. Breast Care. 2026:1-15. doi:10.1159/000552643

BibTeX
@article{Warwas2026,
  author = {Warwas, Karsten M and Volckmar, Anna-Lena and Kazdal, Daniel and Ball, Markus and Smetanay, Katharina and Maurer, Christian and Fremd, Carlo and Sych, Lea and Thewes, Verena and Budczies, Jan and Stenzinger, Albrecht and Schneeweiss, Andreas and Michel, Laura L},
  title = {Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice},
  journal = {Breast Care},
  year = {2026},
  pages = {1--15},
  doi = {10.1159/000552643}
}
Kostenlos starten →